Farage(人非霍奇金淋巴瘤細(xì)胞)
CBP60668
                       
                         詢  價(jià)
                        
                        
                索取STR
                        
                    產(chǎn)品描述
                    產(chǎn)品數(shù)據(jù)庫
                    
                | I. General information | |
| Synonyms: | Farage | 
| Background: | The Farage cell line was adapted to culture in 1990 from a lymph node biopsy of a patient with diffuse large cell non-Hodgkin's lymphoma (DLCL). | 
| Species: | Homo sapiens, human | 
| Tissue: | derived from metastatic site: lymph node | 
| Disease: | non-Hodgkin's B cell lymphoma | 
| Gender: | White, female, adult | 
| Morphology: | lymphoblast | 
| Growth Mode: | suspension | 
| Doubling Time: | 24 to 36 hrs | 
| DNA Profile: | Amelogenin: X CSF1PO: 11,12 D13S317: 11,13 D16S539: 11,12 D5S818: 12 D7S820: 12 THO1: 8,9 TPOX: 9 vWA: 14,15 Our Cell Line Authentication Service | 
| Culture Medium: | RPMI-1640+10%FBS+0.05 mM 2-mercaptoethanol Farage完全培養(yǎng)基,# CBP60668M | 
| Cryopreservation medium: | 90%FBS+10%DMSO | 
| Antigen Expression: | CD10 +/-; CD11a + (LFA-1); CD19 +; CD20 +; CD21 +; CD22 +; CD23 +; CD29 (VLA-4) +; CD38 +; CD39 +; CD40 +; CD44 +; CD54 + (ICAM-1); CD58 + (LFA-3); CD23 -; HLA DR + | 
| Comments: | The cells do not express surface or cytoplasmic immunoglobulin.Exposure of Farage cells to phorbol 12-myristate 13-acetate (PMA) down-regulated CD21 and CD23 expression.hey do not express the terminal deoxynucleotydyl transferase gene (TdT), nor the recombination activating genes RAG-1 and RAG-2, known as markers of the pre-B cell stage. These results show that Farage represents a mature B-cell rather than a pre-B cell. Exposure to IL-4 augmented the concentrations of CD23, CD54, and CD58 but diminished the expression of CD21, CD22, and CD38. Incubation with IL-4 for 6 to 8 days led to increased expression of CD11a, CD39, CD40, and to disappearance of CD21 and CD38.The cells are positive for Epstein-Barr virus (EBV). mature B cel For more information, please contact us (4008-750-250). | 
 
            
 
             
             
         
             
             
             
             
             
             
            